| Literature DB >> 32942016 |
Tiago Rodrigues1, Patrícia Borges2, Laura Mar2, Daniela Marques2, Miguel Albano3, Hans Eickhoff4, Catarina Carrêlo2, Bruno Almeida5, Salomé Pires6, Margarida Abrantes6, Beatriz Martins7, Cristina Uriarte3, Filomena Botelho6, Pedro Gomes3, Sónia Silva8, Raquel Seiça1, Paulo Matafome9.
Abstract
Methylglyoxal was shown to impair adipose tissue capillarization and insulin sensitivity in obese models. We hypothesized that glyoxalase-1 (GLO-1) activity could be diminished in the adipose tissue of type 2 diabetic obese patients. Moreover, we assessed whether such activity could be increased by GLP-1-based therapies in order to improve adipose tissue capillarization and insulin sensitivity. GLO-1 activity was assessed in visceral adipose tissue of a cohort of obese patients. The role of GLP-1 in modulating GLO-1 was assessed in type 2 diabetic GK rats submitted to sleeve gastrectomy or Liraglutide treatment, in the adipose tissue angiogenesis assay and in the HUVEC cell line. Glyoxalase-1 activity was decreased in visceral adipose tissue of pre-diabetic and diabetic obese patients, together with other markers of adipose tissue dysfunction and correlated with increased HbA1c levels. Decreased adipose tissue GLO-1 levels in GK rats were increased by sleeve gastrectomy and Liraglutide, being associated with overexpression of angiogenic and vasoactive factors, as well as insulin receptor phosphorylation (Tyr1161). Moreover, GLP-1 increased adipose tissue capillarization and HUVEC proliferation in a glyoxalase-dependent manner. Lower adipose tissue GLO-1 activity was observed in dysmetabolic patients, being a target for GLP-1 in improving adipose tissue capillarization and insulin sensitivity.Entities:
Keywords: Adipose tissue; Capillarization; GLP-1; Glyoxalase; Insulin resistance; Liraglutide
Year: 2020 PMID: 32942016 DOI: 10.1016/j.phrs.2020.105198
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658